Spectral AI spent more than a decade as a government-funded burn-imaging developer, and that identity officially ended when the Food and Drug Administration granted De Novo classification for the DeepView System in late May. The classification authorizes commercial distribution in the United States for the burn indication, which is the event the Avenue credit line, the BARDA follow-on options, and the rebuilt commercial bench were all waiting on. What the classification does not do is put a product invoice on the income statement. Mid-year results still show a contract shop whose only customer of consequence is a single federal agency, and management is still pointing to year-end for the first commercial sale rather than reporting one.
The second-quarter print is the financial signature of that in-between state. Research revenue fell as the BARDA Project BioShield contract shifted into a cost-share follow-on phase after clearance, so the same work that used to be fully reimbursed now leaves a larger residual on Spectral's own books. Gross margin compressed because that mix is structurally less generous, while selling costs rose as the company hired a commercial chief and paid for pricing work it could not justify before clearance. The June Avenue draw of $6.5 million is the other side of the same coin. The lender released the second tranche only after the regulator acted, which extends the interest-only window but also puts more floating-rate paper ahead of common equity.
Full-year revenue guidance of about $18.5 million still assumes almost no product contribution. Cash of $14 million sits next to roughly the same amount of notes, a warrant liability nearly as large as cash, and a standby equity line that prices at a discount to the tape. The investment debate is no longer whether DeepView can be sold. It is whether hospitals actually buy it, on what mix of capital equipment and software licenses, before BARDA's remaining options and the Avenue and Yorkville backstops become the entire story again.